Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Nivolumab (Primary) ; Synthetic vaccines (Primary) ; Poly ICLC; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions
- 17 Oct 2018 Planned End Date changed from 31 Dec 2027 to 31 Jan 2028.
- 17 Oct 2018 Planned primary completion date changed from 30 Jun 2022 to 31 Jul 2022.
- 17 Oct 2018 Status changed from not yet recruiting to recruiting.